Find information on thousands of medical conditions and prescription drugs.

Trimipramine

Trimipramine is an tricyclic antidepressant with sedative and anxiolytic properties. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Pharmacology

Trimipramine's mechanism of action differs from other tricyclic antidepressants. It is only a moderate reuptake inhibitor of norepinephrine, and a weak reuptake inhibitor of serotonin and dopamin. The main effects are due to considerable postynaptic blockage as follows:

  • strong : 5-HT2, Muscarinic, H1, H2, Alpha1
  • moderate : D2
  • weak : 5-HT1, Alpha2

The spectrum of effects (strong antidepressant activity, sedation and anxiolysis) and side-effects (strong anticholinergic and antiadrenergic side-effcts) is the same as with Doxepin. It is also a more effective sedative than Amitriptyline. Trimipramine is the only effective drug against insomnia known so far that does not alter the normal sleep architecture. In particular, it does not suppress REM-sleep. Moreover, dreams are said to brighten during treatment. Its relatively strong antagonistic activity at postsynaptic D2-receptors led to a clinical study trying Trimipramine as atypical neuroleptic. There it exerted good antipsychotic activity with a low incidence of extrapyramidal and other side-effects. But this study encompassed only 28 patients, so the use of Trimipramine as a neuroleptic needs further confirmation and can currently not be recommended. Trimipramine shows also useful activity against chronic pain.

Indications

  • Endogenous and neurotic depression with prominent agitation and anxiety
  • Depressive and non-depressive insomnia (suitable for long-term treatment)
  • Adjunctive therapy of alcohol and opioid withdrawal
  • Chronic pain of malignant and non-malignant origin

Trimipramine is an efficient antidepressant, sedative, and anxiolytic comparable to Doxepin.

Contraindications

absolute :

  • concomittant treatment with MAO-Inhibitors
  • known hypersensitivity to Trimipramine or other Tricyclics
  • acute intoxication with alcohol, sedatives, analgesics and other psychoactive drugs
  • acute Delirum tremens
  • untreated closed angle glaucoma
  • hypertrophy of the prostate with urine retention
  • paralytic ileus

relative :

  • hypertrophy of the prostate without urine retention
  • reduced function of the bone marrow
  • organic brain disorders
  • increased risk of seizures, preexisting epilepsy
  • preexisting cardial damage, particular some arrhythmias (impulse conductive disorders)

Side Effects

See the article on Doxepin. All side-effects of Doxepin are noted also during Trimipramine use with approximately the same frequency and intensity in equivalent doses.

Read more at Wikipedia.org


[List your site here Free!]


Depression in the Long-Term Care Setting
From American Family Physician, 5/15/02 by Grace Brooke Huffman

Elderly patients living in the nursing home setting are up to five times more likely to have depression, but fewer than one fourth are adequately treated. Physicians may believe that other medical conditions are causing the depression or that other medical conditions may make treatment of depression contraindicated. In addition, there is little evidence about the optimal treatment of depression in elderly patients. Brown and associates performed a cross-sectional study and describe management of this condition.

A database used by the Health Care Financing Administration (HCFA) was the source of data for this study. All Medicaid and Medicare-certified nursing homes in Kansas, Maine, Mississippi, New York, and South Dakota were included. Medications given to each resident were recorded, and antidepressants were classified as tricyclics (amitriptyline, imipramine, doxepin, amoxapine, protriptyline, nortriptyline, trimipramine, and desipramine), tetracyclic (maprotiline), selective serotonin reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine), monoamine oxidase inhibitors (phenelzine, isocarboxazid, and tranylcypromine), and others (venlafaxine, trazodone, bupropion, and nefazodone).

Of the 428,055 residents included in the study, 46,677 were diagnosed with depression. The diagnosis occurred more often in women than in men and more often in non-Hispanic white patients than those with other ethnic backgrounds. One half (55 percent) of those with this diagnosis received an antidepressant. Many of these patients were given less than the manufacturer's recommended dosage, although the authors acknowledge that some of the antidepressants may have been prescribed for indications other than depression.

Patients who were 85 years of age or older were less likely to be given treatment than younger patients, and blacks were less likely to be given treatment than whites. Patients with cancer or more than six diagnosed clinical conditions were less likely to take antidepressants. On the other hand, patients with diabetes mellitus or cerebrovascular disease were more likely to receive antidepressants.

The authors concur with the recommendations of the National Institutes of Health Consensus Development Conference on Diagnosis and Treatment of Depression in Late Life, that elderly patients with depression should be given adequate dosages of antidepressants and continue taking them for an appropriate length of time to maximize the likelihood of recovery. Up to 80 percent of these patients respond well to such treatment.

Physicians should be aware that, in the elderly patient, depression may be difficult to distinguish from other conditions (such as dementia), and patients may present with symptom profiles that are different from those of younger patients. Finally, elderly patients may not have full-blown depression but, in this population, a symptom complex representing subsyndromal depression may be amenable to treatment.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Trimipramine
Home Contact Resources Exchange Links ebay